Trial Profile
Phase II Study of Erlotinib in Patients With Non-Metastatic Prostate Cancer With a Rising PSA on Hormone Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 24 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jun 2011 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Additional lead trial centre and lead investigator identified as reported by ClinicalTrials.gov.